Pradigastat sodium

Overview

Pradigastat sodium (LCQ 908 sodium) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC 50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP , OATP1B1, OATP1B3 and OAT3 activities with IC 50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Infection | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Acyltransferase | Products > Signaling Pathways > BCRP | Products > Signaling Pathways > OAT

Product Information

• Catalog No.: HY-16278A
• CAS No.: 956136-98-4
• Molecular Formula: C25H23F3N3NaO2
• Molecular Weight: 477.45
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source